Lantern updates ongoing Phase 2 HARMONIC trial for ‘Never Smokers’

Lantern Pharma announced positive, preliminary results from the initial patient group in the ongoing HARMONIC phase 2 clinical trial. HARMONIC is evaluating Lantern Pharma’s investigational new drug candidate, LP-300, in combination with pemetrexed and carboplatin in never smokers1 with advanced non-small cell lung cancer NSCLC who have progressed after receiving treatment with a tyrosine kinase inhibitor TKI. LP-300 was advanced in part with Lantern’s AI platform, RADR, to aid in the validation of mechanisms and uncover insights in targeted patient populations. RADR is Lantern’s AI platform for cancer therapy discovery, development and rescue with over 100 billion data points and aiding in the development of both Lantern’s portfolio and development initiatives with Lantern’s collaborators…